Shockwave Therapy Benefits and Side Effects

What Benefits Might Shockwave Therapy Offer?

The most consistently studied benefits are reductions in patient-reported pain and improvements in self-reported function for selected chronic tendon and fascia conditions that have not responded to first-line care. These are patient-reported outcomes, not imaging-based structural repair. Where structural outcomes have been evaluated—for example, calcification resorption in rotator cuff tendinopathy—results are less uniform than pain outcomes.

Two boundaries matter. A statistically significant change on a pain scale is not automatically a clinically meaningful change for an individual patient. And benefit in one condition, with one device type and one protocol, does not transfer automatically to another condition or device.

What Does Clinical Evidence Show by Condition?

Plantar Fasciitis

NICE reviewed extracorporeal shockwave therapy for refractory plantar fasciitis and concluded that the evidence “raises no major safety concerns; however, current evidence on its efficacy is inconsistent”. NICE recommended use only with special arrangements for clinical governance, consent, and audit or research, and encouraged further research with validated outcomes and at least one-year follow-up. That is a conditional position, not an endorsement.

Later meta-analyses have reported pain and function improvements with moderate- and high-intensity ESWT, with calcaneal pain and erythema more frequent in ESWT groups. The direction of benefit is plausible; certainty is limited by heterogeneity in devices, energy levels, and protocols.

Tendinopathies and Lateral Epicondylitis

For chronic lateral epicondylitis, a 2024 systematic review and meta-analysis of six RCTs compared ESWT with local corticosteroid injection. ESWT was inferior at one month but superior at three and six months for pain and grip strength, with a similarly low rate of mild adverse events (OR 0.69, 95% CI 0.05–8.60). PRTEE improvement favored ESWT at three months. The six-month PRTEE comparison should not be described as a confirmed significant advantage without direct verification in the source data; the clearly reported long-term advantages are for pain and grip strength.

That pattern—slower onset, better durability—is clinically relevant, but it is a comparison against injection, not against sham or natural history.

Calcific and Non-Calcific Shoulder Conditions

In rotator cuff calcific tendinitis, a 2025 network meta-analysis of 33 RCTs covering 26 treatments ranked comprehensive physical therapy first for functional improvement, followed by high-energy ESWT plus physical therapy; for pain relief, radial ESWT plus physical therapy ranked highest by SUCRA. SUCRA rankings indicate probability of being among the better treatments in the network, not that every pairwise difference between treatments is statistically significant. This suggests a role for ESWT as part of a multimodal program, not necessarily as monotherapy. For non-calcific rotator cuff tendinopathy, comparative evidence is thinner and does not support extrapolating the calcific tendinopathy findings.

Other Musculoskeletal Conditions: Where Evidence Is Limited

For Achilles tendinopathy, the evidence has moved in a negative direction. A 2026 systematic review and meta-analysis of nine RCTs (n = 557) found no clinically meaningful benefit of shockwave therapy over sham for insertional Achilles tendinopathy (low-to-moderate certainty), and no significant differences in disability or pain for midportion Achilles tendinopathy at any timepoint. The authors concluded that shockwave therapy should not be considered a routine treatment for either presentation. Two Achilles tendon ruptures were reported following focused shockwave therapy in that review, within the specific trials that used focused protocols; causality has not been established, and these events should not be interpreted as a risk rate applicable to all shockwave devices.

For other conditions—patellar tendinopathy, medial epicondylitis, hip abductor tendinopathy, and various fracture-healing applications—the evidence is preliminary, inconsistent, or too device-specific to support a general claim. These are areas of active investigation, not established benefits.

Common Side Effects After Shockwave Therapy

Across systematic reviews, the most frequently reported effects are pain during application and transient skin redness. In a 2017 systematic review of complications in plantar fasciitis covering 39 studies and 2,493 patients, 225 patients reported pain during treatment and 247 reported transient red skin after treatment; other reported effects included transient post-treatment pain, dysesthesia, swelling, ecchymosis and/or petechiae, severe headache, bruising, and a throbbing sensation. These are aggregated event counts across heterogeneous study populations, not standardized incidence rates applicable to all patients.

For radial pressure wave therapy, potential side effects include applicator-site pain, skin erythema, bruising, hematoma formation, nerve irritation, superficial edema, and headache. Focused shockwave therapy shares the applicator-site pain, erythema, bruising, and hematoma profile. These effects are generally self-limited and do not require discontinuation in most published series, but they are not zero and should be discussed before treatment.

Less Common but Important Risks

Serious adverse events are uncommon in musculoskeletal trials but not absent. The most clinically significant signal in recent literature is tendon rupture. The 2026 Achilles tendinopathy meta-analysis reported two Achilles tendon ruptures after focused shockwave therapy, and published case reports describe both distractive and delayed ruptures in patients with chronic tendinopathy. Causality is difficult to establish in individual cases—degenerative tendons can rupture spontaneously—but the temporal association warrants caution. No published head-to-head trial has established that high-energy focused protocols carry a uniquely higher rupture risk than other modalities; the association has been documented in patients with pre-existing degenerative tendinopathy and warrants informed consent regardless of device energy class.

Other reported serious events in the broader shockwave literature include superficial skin infection, precordial pain in a patient with a cardiac history, and nerve-related symptoms. Device labeling may list additional warnings. The accurate framing is that these events are rare, not impossible.

What Influences Benefits and Side Effects?

At least five variables change the balance of benefit and risk: device type (focused versus radial), energy level, treatment protocol, target tissue, and patient selection. The same condition treated with a low-energy radial protocol and a high-energy focused protocol is not the same intervention in mechanistic or clinical terms.

This is why NICE required protocols to describe local anesthesia use and the type of energy applied, and why network meta-analyses find different rankings for different energy levels and device types. It is also why a finding in lateral epicondylitis cannot be assumed to hold for Achilles tendinopathy, or vice versa.

How to Interpret the Clinical Evidence

Four distinctions help prevent over-reading the literature.

Pain versus function versus structure. Most positive trials report pain and patient-reported function. Structural outcomes—calcification resorption, tendon thickness, MRI cartilage change—are less consistently improved and should not be inferred from pain relief.

Sham-controlled versus usual-care-controlled versus injection-controlled. A trial showing superiority to injection at six months answers a different question from a trial showing no difference from sham. Both are relevant, but they support different claims.

Certainty, not just significance. A meta-analysis can report a significant pooled effect based on very low-certainty evidence. The Achilles tendinopathy review is a clear example: most effect estimates were based on very low- to low-certainty data, and the authors cautioned that true effects may change with future trials.

Regulatory status is not the same as clinical evidence. In the United States, product code NBN—Generator, Shock-Wave, For Pain Relief—is a Class III device category requiring Premarket Approval (PMA). FDA authorization is device-specific and indication-specific; it is not a judgment that every studied use is effective. For contraindications and patient selection, see Who Should Not Receive Shockwave Therapy?

Conclusion

Shockwave therapy has a real but conditional role in musculoskeletal care. The strongest evidence is for chronic plantar fasciitis and lateral epicondylitis, with caveats about evidence certainty and protocol variability. For Achilles tendinopathy, recent high-quality syntheses do not support routine use. Side effects are mostly transient and mild, but tendon rupture is a recognized rare risk that should be part of informed consent.